Solid Tumor, Adult Clinical Trials in Los Angeles, California
9 recruitingLos Angeles, California
Showing 1–9 of 9 trials
Recruiting
Phase 1
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
Endometrial CancerColorectal CarcinomaNon-small Cell Lung Cancer+3 more
AstraZeneca108 enrolled18 locationsNCT06218914
Recruiting
Phase 1
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Metastatic Breast CancerAdvanced Breast CancerMetastatic Lung Cancer+6 more
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)392 enrolled31 locationsNCT06625775
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Solid Tumor, Adult
A2 Biotherapeutics Inc.474 enrolled12 locationsNCT06051695
Recruiting
Phase 1
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Ovarian CancerOvarian CarcinomaAdvanced Solid Tumor+8 more
NiKang Therapeutics, Inc.150 enrolled19 locationsNCT06586957
Recruiting
Phase 1Phase 2
Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab
Solid Tumor, Adult
Linnaeus Therapeutics, Inc.200 enrolled10 locationsNCT04130516
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Solid Tumor, Adult
A2 Biotherapeutics Inc.240 enrolled10 locationsNCT06682793
Recruiting
Phase 1
A Study of VET3-TGI in Patients With Solid Tumors
Cervical CancerNon-small Cell Lung CancerHead and Neck Squamous Cell Carcinoma+7 more
KaliVir Immunotherapeutics60 enrolled7 locationsNCT06444815
Recruiting
Phase 1Phase 2
Study of DF1001 in Patients with Advanced Solid Tumors
Solid Tumor, Adult
Dragonfly Therapeutics378 enrolled52 locationsNCT04143711
Recruiting
Phase 1Phase 2
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Solid Tumor, AdultCutaneous MelanomaRefractory Cancer+3 more
GV20 Therapeutics365 enrolled13 locationsNCT05669430